Lifecore Biomedical, Inc. (NASDAQ:LFCR) Receives Average Rating of “Hold” from Analysts

Shares of Lifecore Biomedical, Inc. (NASDAQ:LFCR) have earned an average recommendation of “Hold” from the five analysts that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and two have issued a buy recommendation on the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $5.50.

A number of analysts have recently issued reports on LFCR shares. Zacks Research raised Lifecore Biomedical to a “hold” rating in a research report on Thursday, January 1st. Barrington Research raised Lifecore Biomedical from a “market perform” rating to an “outperform” rating and set a $5.50 price target for the company in a report on Tuesday. Finally, Weiss Ratings restated a “sell (d)” rating on shares of Lifecore Biomedical in a research note on Thursday, January 22nd.

Lifecore Biomedical Stock Performance

NASDAQ:LFCR opened at $4.36 on Tuesday. The company has a debt-to-equity ratio of 113.76, a current ratio of 2.80 and a quick ratio of 1.67. The firm has a 50-day moving average of $7.54 and a two-hundred day moving average of $7.49. The stock has a market cap of $163.37 million, a P/E ratio of -4.07 and a beta of 0.62. Lifecore Biomedical has a 1-year low of $4.20 and a 1-year high of $8.98.

Institutional Trading of Lifecore Biomedical

Hedge funds have recently made changes to their positions in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Lifecore Biomedical by 14.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 14,785 shares of the company’s stock worth $104,000 after buying an additional 1,886 shares during the last quarter. Steward Partners Investment Advisory LLC raised its holdings in Lifecore Biomedical by 8.4% in the second quarter. Steward Partners Investment Advisory LLC now owns 32,761 shares of the company’s stock valued at $266,000 after acquiring an additional 2,528 shares in the last quarter. BNP Paribas Financial Markets boosted its stake in Lifecore Biomedical by 92.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 5,791 shares of the company’s stock valued at $43,000 after acquiring an additional 2,786 shares during the last quarter. Price T Rowe Associates Inc. MD grew its holdings in Lifecore Biomedical by 20.4% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 16,646 shares of the company’s stock worth $137,000 after acquiring an additional 2,826 shares in the last quarter. Finally, AQR Capital Management LLC grew its holdings in Lifecore Biomedical by 28.4% during the 4th quarter. AQR Capital Management LLC now owns 16,171 shares of the company’s stock worth $132,000 after acquiring an additional 3,574 shares in the last quarter. Institutional investors and hedge funds own 83.36% of the company’s stock.

About Lifecore Biomedical

Lifecore Biomedical, Inc is a publicly traded specialty biopharmaceutical company headquartered in Chaska, Minnesota. The company focuses on the development, manufacture and commercialization of hyaluronic acid (HA)–based products that address medical and aesthetic needs. Lifecore’s proprietary HA formulations are designed to meet strict regulatory standards for purity, consistency and performance in highly regulated markets.

The company’s product portfolio spans multiple therapeutic areas, including ophthalmology, orthopedics, dermatology and wound care.